Coronavirus Update: Takeda Contractor To Manufacture J&J Vaccine; Moderna Starts Pediatric Trial
Also, GSK Begins Vaccine Trial With Partner Medicago
Takeda agreed with its contract manufacturer to grant access to its dengue vaccine production capacity for Johnson & Johnson's COVID-19 vaccine. Frontrunner Moderna started a pediatric trial in children as young as six months. GSK and Medicago began the Phase III portion of a Phase II/III vaccine trial. And China is limiting inbound travel to people vaccinated with China-made vaccines.
You may also be interested in...
Coronavirus Update: New Funding For Valneva, Scotland Looks At Long COVID
France's Valneva raises new funds to progress its inactivated vaccine, while Scotland launches a new study into 'long COVID', Takeda reports positive interim results from a Japanese trial with Moderna's mRNA vaccine, a setback for GC's plasma therapy, and Celltrion begins exporting a therapeutic antibody.
Pandemic Perspectives: China Vaccine Diplomacy - A World On Shots
Over 50 countries around the world are now receiving COVID-19 vaccine deliveries from China, totaling 3.3 million doses and counting so far. This Scrip infographic shows their locations, quantity of supplies and the developers involved.
Coronavirus Update: How Vaccines Stack Up Against Variants So Far
Plus: Sanofi is getting into the mRNA vaccine game under a partnership with Translate Bio but has a lot of catching up to do.